
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte's financial outlook is bolstered by a 10% year-over-year growth in Jakafi demand across all indications, along with a successful commercial launch of Niktivmo contributing to revenue increases. The firm raised its fiscal year 2025 revenue guidance to between $4.23 billion and $4.32 billion, primarily driven by strong projections for Jakafi and other oncology products, which are now expected to generate $550 million to $575 million. Additionally, the positive market sentiment surrounding Incyte, reflected in a 29% stock increase over the past three months, is supported by robust commercial execution, a positive management shift, and promising clinical results from product pipelines.
Bears say
Incyte's stock outlook appears negative due to several critical risks impacting its financial stability. Primarily, there are concerns regarding eroding pricing power for Jakafi, compounded by poor performance in the earlier-stage pipeline, which could negatively affect future revenue streams. Additionally, potential clinical or regulatory setbacks for Jakafi combinations and adverse market dynamics, including increased competition and reimbursement challenges, heighten the downside risk for the company's overall valuation.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares